Navigation Links
TB Claims One Life Every 17 Seconds; Almost Two Million People Each Year
Date:6/25/2010

New CDC Guidelines Prefer Use of Blood Tests, including QuantiFERON®-TB, to Diagnose Tuberculosis Infection in Certain Populations

Valencia, CA (PRWEB) June 25, 2010 -- The United States (U.S.) Centers for Disease Control and Prevention (CDC) issued new and important guidelines on the detection of Mycobacterium tuberculosis infections, the causative agent of tuberculosis (TB). In these landmark guidelines, CDC advises that Interferon Gamma Release Assay (IGRA) blood tests are now preferred over the 100+-year-old tuberculin skin test (TST) for diagnosing TB infection in certain populations, including people who typically do not return for the necessary reading of TST results, and those who have received Bacille Calmette-Guérin (BCG) as a vaccine or for cancer therapy. Typically the TST or IGRAs, such as QuantiFERON®-TB Gold (QFT), manufactured by Cellestis Limited, should be used as aids to diagnose infection with M. tuberculosis.

Developing countries are in a constant battle against the ravaging effects of the tuberculosis crisis. With global migration and the highly contagious nature of tuberculosis, the disease remains a significant threat to public health in the U.S. Settling into the lungs, the spine, the kidneys and the brain, tuberculosis can be fatal without proper treatment. The CDC estimates that up to 14 million people in the U.S. are TB infected and asymptomatic - with three-quarters remaining undiagnosed - and at risk of progressing to highly contagious TB disease.

For more information, please visit www.TackleTB.com.

TB disease can be prevented by treating the symptomless infection before disease strikes. Convenient and trustworthy testing for TB infection is vital in order to quickly identify people needing treatment and thereby preventing the spread of TB. QFT is sound, evidence-based technology that virtually eliminates false positive results and more definitively indicates when a patient is infected with the TB bacterium. For the uninfected individual, this spares the anxiety and concern that a positive TST result, which may often be falsely positive, may cause. A false-positive TB test usually leads to unwarranted medical consultations and often, unnecessary treatment. For those unfortunate enough to be infected, the higher accuracy of QFT (over TST) greatly increases the likelihood that their infection will be detected. Use of QFT provides significant risk reduction for the millions of health professionals, employees, patients, and individuals who may come in contact with TB in the course of their work.

About QuantiFERON-TB Gold (QFT)
QuantiFERON-TB Gold (QFT) is a simple blood test that accurately identifies people infected with Mycobacterium tuberculosis, the causative agent of Tuberculosis (TB). As a modern alternative to the 110 year old Tuberculin Skin Test (TST), also known as the Mantoux, QFT offers unmatched specificity, high sensitivity and simplicity. QFT enables focused TB therapy by providing clinicians with an accurate, reliable and convenient TB diagnostic tool. QFT is unaffected by previous BCG vaccination and most other environmental mycobacteria. Unlike the TST, it requires only one patient visit, is a controlled laboratory test and provides an objective, reproducible result that is unaffected by subjective interpretation. Results can be available within 24 hours.

QFT is available for use in all clinical settings in which TST is commonly used. Examples include contact tracing, regular employee testing, for example for health care workers, as well as screening programs for prisoners and immigrants. QFT's application offers distinct advantages over the TST in the screening of immunosuppressed patients prior to anti-TNF-alpha therapy initiation and in patients with HIV, cancer or organ transplants.

QFT is sold directly in the U.S. by Cellestis Inc; in Europe by Cellestis GmbH (Germany); and in Australia and Asia by Cellestis International Pty. Ltd. (Australia). QFT is also available through Cellestis Commercial Partners in Japan, Europe, the Middle East and other countries around the world.

Multimedia Release: Multimedia Content Attached

# # #

Read the full story at http://www.prweb.com/releases/2010/06/prweb4189974.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Many Supplements Said to Contain Toxins, Make False Health Claims
2. Osteoarthritis Claims Growing Number of Younger Victims
3. FDA to Take Up Major Enforcement Action Against Cosmetics Manufacturers With Illegal “Anti-Aging” Labeling Claims, According to FDAImports.com, LLC
4. Salt Lake City proclaims Molecular Imaging Days during SNMs Annual Meeting in June
5. BPA in Cans Poses Health Threat, Report Claims
6. False Claims Act Attorney Tim Terry to Address Arizona Chapter of the Association of Certified Fraud Examiners
7. Health Claims on Foods May Not Be Well-Grounded
8. Martin & Jones Announces Class Action Lawsuit Against Major Employer, Claims Thousands of Visiting Nurses Illegally Denied Overtime Pay
9. KEL Attorneys is Assisting Victims of the Deepwater Horizon Oil Spill by Filling Legal Claims on Their Behalf
10. Assessing the science behind health claims
11. Allsup Outlines Quick-Processing Methods for Social Security Disability Claims
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
TB Claims One Life Every 17 Seconds; Almost Two Million People Each Year 
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a ... and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is ... to some of the world’s leading providers of cereal and other breakfast foods. Its ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as ... Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) ... Daylight Time). As previously announced on May ... definitive merger agreement under which Jazz Pharmaceuticals has commenced ...
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... -- Dehaier Medical Systems Ltd. (NASDAQ: DHRM ... sells medical devices and wearable sleep respiratory products in ... agreement with Hongyuan Supply Chain Management Co., Ltd. (hereinafter ... 2016, to develop Dehaier,s new Internet medical technology business. ... leverage Hongyuan Supply Chain,s sales platform to reach Dehaier,s ...
Breaking Medicine Technology: